In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
|Articles|October 7, 2021
Medication Pearl of the Day: Tisotumab Vedotin (Tivdak) for Cervical Cancer
Author(s)Saro Arakelians, PharmD
Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Advertisement
Medication Pearl of the Day: Tisotumab vedotin (Tivdak)
Indication: Tisotumab vedotin is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Insight:
- Dosage: For intravenous (IV) infusion only. The recommended dose of tisotumab vedotin is 2 mg/kg (up to a maximum of 200 mg) given as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
- Dosage form: For injection, 40 mg as a lyophilized cake or powder in a single-dose vial for reconstitution.
- Adverse Events (AEs): The most common (≥25%) AEs include laboratory abnormalities, decreased hemoglobin, fatigue, decreased lymphocytes, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival AEs, hemorrhage, decreased leukocytes, increased creatinine, dry eye, increased prothrombin international normalized ratio, prolonged activated partial thromboplastin time, diarrhea, and rash.
- Drug interaction: Strong CYP3A4 Inhibitors—closely monitor for tisotumab vedotin AEs.
- Mechanism of Action: Tisotumab vedotin, a TF-directed antibody drug conjugate, is a human immunoglobulin 1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade.
- Manufacturer: Seagen/Genmab
Sources:
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
Community Pharmacists Guide Patients New to Glucose Monitoring
5